Home >> Behavioral Health >> Behavioral Health >> Baby Food >> Technology & Media >>

Reperfusion Injury - Pipeline Review, H1 2013

Published: Jun-2013 | Format: PDF | Global Markets Direct | Number of pages: 144 | Code: MRS - 980

Global Markets Direct’s, 'Reperfusion Injury - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Reperfusion Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Reperfusion Injury. 

Reperfusion Injury - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

A snapshot of the global therapeutic scenario for Reperfusion Injury.
A review of the Reperfusion Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Reperfusion Injury pipeline on the basis of route of administration and molecule type.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy


Identify and understand important and diverse types of therapeutics under development for Reperfusion Injury.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Reperfusion Injury pipeline depth and focus of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

TABLE OF CONTENT

Introduction
Global Markets Direct Report Coverage
Reperfusion Injury Overview
Therapeutics Development
An Overview of Pipeline Products for Reperfusion Injury
Reperfusion Injury Therapeutics under Development by Companies
Reperfusion Injury Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Reperfusion Injury Therapeutics – Products under Development by Companies
Reperfusion Injury Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Reperfusion Injury Therapeutics Development
Pharming Group N.V.
BioLineRx, Ltd.
Teva Pharmaceutical Industries Limited
Proteo, Inc.
NeuroVive Pharmaceutical AB
SCYNEXIS, Inc.
Prolong Pharmaceuticals
Trophos SA
Curatis Pharma GmbH
Alligator Bioscience AB
Opsona Therapeutics Ltd.
PledPharma AB
Omeros Corporation
Bolder Biotechnology, Inc.
Max Planck Innovation GmbH
ADIENNE Pharma & Biotech
Dr. Franz Kohler Chemie GmbH
GENEXTRA S.p.A.
APEPTICO Forschung und Entwicklung GmbH
ToleroTech Inc.
Mt Cook Pharma. Inc.
Ischemix
Reperfusion Injury – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
PMX-53 - Drug Profile
CGEN-855A - Drug Profile
CGEN-855B - Drug Profile
Elafin - Drug Profile
TRO-40303 - Drug Profile
ADC-1004 - Drug Profile
OMS-721 - Drug Profile
CMX-2043 - Drug Profile
MTP-131 - Drug Profile
CicloMulsion - Drug Profile
Evasin-3 - Drug Profile
conestat alfa - Drug Profile
BBT-045 - Drug Profile
EU-C-002 - Drug Profile
AP-301 - Drug Profile
OPN-305 - Drug Profile
MCP-205 - Drug Profile
Sanguinate - Drug Profile
Custodiol-N - Drug Profile
sodium nitrite - Drug Profile
Curaglutide - Drug Profile
CMX-272XX - Drug Profile
ADAM17 Inhibitor - Drug Profile
EDP-09 - Drug Profile
APT-102 - Drug Profile
Cyclophilin Inhibitory Compounds - Drug Profile
Drug Targeting Neuronal Nitric Oxide Synthase - Drug Profile
NKT II Cell Modulator - Drug Profile
ARA-290 - Drug Profile
XGP-610 - Drug Profile
PNU-282987 - Drug Profile
alpha-1-antitrypsin - Drug Profile
PP-099 - Drug Profile
Type 5 Adenylyl Cyclase Inhibitors - Drug Profile
Beta 2-Glycoprotein I Peptides - Drug Profile
Drug For Reperfusion Injury - Drug Profile
caffeic acid phenethyl ester - Drug Profile
mPTP Inhibitors - Drug Profile
Drug For Ischemia/Reperfusion Injury - Drug Profile
siIschemia - Drug Profile
Compound 9 - Drug Profile
PIN-201601 - Drug Profile
Glutathione Peroxidase Mimetic Compounds - Drug Profile
Ixac - Drug Profile
Na/K-ATPase-Specific Src Modulator - Drug Profile
PVIIA - Drug Profile
RIIIK - Drug Profile
Reperfusion Injury Therapeutics – Drug Profile Updates
Reperfusion Injury Therapeutics – Discontinued Products
Reperfusion Injury Therapeutics - Dormant Products
Reperfusion Injury – Product Development Milestones
Featured News & Press Releases

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products Under Development for Reperfusion Injury, H1 2013
Products under Development for Reperfusion Injury – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Number of Products under Development by Companies, H1 2013 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2013
Comparative Analysis by Late Stage Development, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
Products under Development by Companies, H1 2013 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2013
Pharming Group N.V., H1 2013
BioLineRx, Ltd., H1 2013
Teva Pharmaceutical Industries Limited, H1 2013
Proteo, Inc., H1 2013
NeuroVive Pharmaceutical AB, H1 2013
SCYNEXIS, Inc., H1 2013
Prolong Pharmaceuticals, H1 2013
Trophos SA, H1 2013
Curatis Pharma GmbH, H1 2013
Alligator Bioscience AB, H1 2013
Opsona Therapeutics Ltd., H1 2013
PledPharma AB, H1 2013
Omeros Corporation, H1 2013
Bolder Biotechnology, Inc., H1 2013
Max Planck Innovation GmbH, H1 2013
ADIENNE Pharma & Biotech, H1 2013
Dr. Franz Kohler Chemie GmbH, H1 2013
GENEXTRA S.p.A., H1 2013
APEPTICO Forschung und Entwicklung GmbH, H1 2013
ToleroTech Inc., H1 2013
Mt Cook Pharma. Inc., H1 2013
Ischemix, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Reperfusion Injury Therapeutics – Drug Profile Updates
Reperfusion Injury Therapeutics – Discontinued Products
Reperfusion Injury Therapeutics – Dormant Products
List of Figures

Number of Products under Development for Reperfusion Injury, H1 2013
Products under Development for Reperfusion Injury – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Products under Investigation by Universities/Institutes, H1 2013
Late Stage Products, H1 2013
Mid Clinical Stage Products, H1 2013
Early Clinical Stage Products, H1 2013
Discovery and Pre-Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing